Merck plans $3 billion cost cuts by end of 2027, narrows full-year outlook

Last updated: July 29, 2025 4:12 pm

0 Min Read

The multi-year effort comes as Merck prepares to offset revenue losses from the upcoming patent expiration of its blockbuster cancer drug Keytruda.

Share This Article